MedTrace Logo

Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer

NCT06451211 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2024-06-11

No results posted yet for this study

Summary

The aim of this study is to test the efficacy and safety of immunotherapy plus chemotherapy on people with a relatively rare type of gastric cancer. Participants will take the anti-PD-1 inhibitor (Tislelizumab) and platinum-based chemotherapy (oxaliplatin + capecitabine or oxaliplatin + S-1) in a 3-week cycle, followed by a radical operation after 6 cycles.

Conditions

Interventions

DRUG

Tislelizumab

Tislelizumab 200 mg will be administered systemically on day 1 of each cycle in all participants

DRUG

Oxaliplatin

Oxaliplatin 150 mg will be administered systemically on day 1 of each cycle in all participants

DRUG

S-1

S-1 40 mg will be administered orally on day 1-14 of each cycle in all participants

DRUG

Capecitabine

Capecitabine 2500 mg will be administered orally on day 1-14 of each cycle in all participants

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Haibo Qiu, MD, Ph.D · Sun Yat-sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-17
Primary Completion
2024-11-30
Completion
2027-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06451211 on ClinicalTrials.gov